---
title: "Pfizer's new cancer drug Mevrometostat has initiated Phase 3 clinical trials in China, showing promising anti-cancer activity in preliminary studies"
description: "Pfizer has initiated an international multicenter Phase 3 clinical trial (MEVPRO-1) to evaluate the efficacy and safety of its new drug mevrometostat in combination with enzalutamide for patients with"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/216394907.md"
published_at: "2024-10-10T02:45:03.000Z"
---

# Pfizer's new cancer drug Mevrometostat has initiated Phase 3 clinical trials in China, showing promising anti-cancer activity in preliminary studies

> Pfizer has initiated an international multicenter Phase 3 clinical trial (MEVPRO-1) to evaluate the efficacy and safety of its new drug mevrometostat in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer. The study plans to recruit 600 patients globally, including 90 from China. Mevrometostat is an EZH2 inhibitor designed to reduce cancer cell proliferation by blocking abnormal gene expression in cancer cells and inducing cell death

According to the financial news app Zhitong Finance, Pfizer (PFE.US) has recently initiated an international multicenter Phase 3 clinical trial (MEVPRO-1) in China, aiming to evaluate the efficacy and safety of PF-06821497 in combination with enzalutamide compared to enzalutamide or docetaxel in patients with metastatic castration-resistant prostate cancer who have previously received abiraterone acetate treatment. The study plans to enroll 600 participants internationally, including 90 in China.

Public information indicates that PF-06821497 (mevrometostat) is an investigational EZH2 inhibitor. According to Pfizer's disclosure during its Oncology Innovation Day in March this year, the company is expected to launch over 8 significant therapies in oncology by 2030, including this EZH2 inhibitor.

EZH2 has become one of the forefront targets in cancer treatment. EZH2 is a histone methyltransferase, and its abnormal expression is associated with the progression and poor prognosis of various cancers, including prostate, breast, lung, and hematologic malignancies. Studies have shown that overexpression of EZH2 can promote cancer initiation and progression through various mechanisms, including silencing tumor suppressor gene expression and promoting genes involved in cell proliferation and survival. Additionally, EZH2 has been shown to promote cancer metastasis by regulating gene expression involved in epithelial-mesenchymal transition.

Mevrometostat is a Pfizer-developed inhibitor targeting EZH2, which can block the abnormal gene expression in cancer cells driven by EZH2 overexpression, leading to reduced cancer cell proliferation, induced cell death, and inhibition of cancer cell migration and invasion, ultimately achieving the goal of cancer treatment.

Based on clinical data disclosed by Pfizer in March this year at the Oncology Innovation Day, the combination therapy of mevrometostat and enzalutamide (Xtandi) showed promising anti-cancer activity in a Phase 1 clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC). Specifically, in patients previously treated with abiraterone, the median radiographic progression-free survival (rPFS) with mevrometostat+enzalutamide treatment was 17.1 months, a significant improvement compared to historical data (rPFS of 4.8 months).

According to ClinicalTrials website, Pfizer initiated a Phase 3 clinical trial (MEVPRO-1 study) in the United States in August this year targeting mCRPC patients previously treated with abiraterone. This also marks Pfizer's clinical research initiation in China ![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/5287161e696b069cff022bd55e0b722d.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Clinical trial results of Mevrometostat (Image source: Pfizer official website)

In addition, Pfizer has recently initiated another Phase 3 study, MEVPRO-2, to evaluate mevrometostat + enzalutamide for metastatic castration-resistant prostate cancer male patients who have not been treated with abiraterone. The Investigational New Drug (IND) application for this indication has also been approved in China and is expected to start in China soon.

Studies have shown that EZH2 inhibitors have demonstrated potential in treating various types of cancers, including B-cell lymphomas, solid tumors, and certain other hematologic malignancies. For example, tazemetostat has been approved for treating some types of hematologic tumors. Meanwhile, there are multiple EZH2 inhibitors under development globally to treat various types of tumors

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 輝瑞在台灣開展新的 Elranatamab 研究，目標是收集現實世界的骨髓瘤數據 | 輝瑞公司（Pfizer Inc.，股票代碼：PFE）正在台灣啓動一項新的觀察性研究，以評估其多發性骨髓瘤藥物 elranatamab 在真實世界中的有效性。該研究旨在跟蹤患者的治療結果和治療模式，儘管尚未開始招募參與者。此舉預計將增強輝瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |
| 這位輝瑞分析師以看空的基調開始覆蓋；以下是週五的五大新啓動 | 華爾街頂級分析師已對多家公司啓動了覆蓋。Baird 的 David Koning 對 Affirm Holdings (AFRM) 給予中性評級，目標價為 55 美元。Piper Sandler 的 Biren Amin 對 OKYO Ph | [Link](https://longbridge.com/en/news/276467088.md) |
| 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) |
| 學習英偉達刺激芯片銷售，AMD 為 “AI 雲” 借款做擔保 | AMD 為擴大市場份額祭出金融 “狠招”！為初創公司 Crusoe 的 3 億美元購芯貸款提供擔保，承諾在其無客户時 “兜底” 租用芯片。這一復刻英偉達 “租卡雲” 路徑的策略雖能短期推高銷量，但也令 AMD 在 AI 需求放緩時面臨更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
